PROCEPT BioRobotics Corp. Announces Preliminary Fourth Quarter and Fiscal Year 2021 Revenue
12 1월 2022 - 6:03AM
PROCEPT® BioRobotics Corporation (Nasdaq: PRCT), a surgical
robotics company focused on advancing patient care by developing
transformative solutions in urology, today reported preliminary
unaudited revenue for the fourth quarter and fiscal year ended
December 31, 2021.
Preliminary, Unaudited Revenue
Highlights:
- Revenue for the fourth quarter of 2021 is expected to be in the
range of $9.8 million to $10.1 million, compared to $3.2 million in
the prior year period.
- Total U.S. revenue of $8.4 million to $8.7 million for the
fourth quarter of 2021
- U.S. system sales and rental revenue of approximately $5.0
million and U.S. handpieces and other consumables revenue of
approximately $3.4 million for the fourth quarter of 2021
- Total International revenue of approximately $1.4 million for
the fourth quarter of 2021
- Fiscal year 2021 revenue is expected to be in the range of
$34.1 million to $34.4 million, compared to $7.7 million in fiscal
year 2020.
“We are very proud to announce that we have
exceeded our revenue expectations in the fourth quarter and fiscal
year,” said Reza Zadno, Chief Executive Officer of PROCEPT. “The
significant growth is being driven by the successful execution of
our strategy to deliver on both new system sales and increased
procedure adoption for Aquablation therapy. Additionally, our
commercial team expansion and physician adoption have been key in
our ability to overcome the disruption COVID-19 has had on elective
procedures. We believe the numerous benefits of our automated
robotic procedure have the ability to change the surgical standard
of care in BPH.”
The Company plans to release its fourth quarter and
full year 2021 financial results in early March 2022. The
preliminary results are unaudited and remain subject to
adjustment.
About PROCEPT BioRobotics
CorporationPROCEPT is a surgical robotics company focused
on advancing patient care by developing transformative solutions in
urology. PROCEPT develops, manufactures and sells the AquaBeam
Robotic System, an advanced, image-guided, surgical robotic system
for use in minimally invasive urologic surgery with an initial
focus on treating benign prostatic hyperplasia, or BPH. BPH is the
most common prostate disease and impacts approximately 40 million
men in the United States. PROCEPT designed Aquablation therapy to
deliver effective, safe and durable outcomes for males suffering
from lower urinary tract symptoms, or LUTS, due to BPH that are
independent of prostate size and shape or surgeon experience.
PROCEPT has developed a significant and growing body of clinical
evidence, which includes nine clinical studies and over 100
peer-reviewed publications, supporting the benefits and clinical
advantages of Aquablation therapy.
Forward Looking Statements
This release contains forward‐looking statements
within the meaning of federal securities laws, including statements
regarding the Company’s preliminary revenue results for the fourth
quarter and year ended December 31, 2021, which involve risks and
uncertainties that could cause the actual results to differ
materially from the anticipated results and expectations expressed
in these forward-looking statements. You are cautioned not to place
undue reliance on these forward-looking statements. Forward-looking
statements are only predictions based on our current expectations,
estimates, and assumptions, valid only as of the date they are
made, and subject to risks and uncertainties, some of which we are
not currently aware. Forward‐looking statements should not be read
as a guarantee of future performance or results and may not
necessarily be accurate indications of the times at, or by, which
such performance or results will be achieved. These forward‐looking
statements are based on PROCEPT’s current expectations and
inherently involve significant risks and uncertainties. Actual
results and the timing of events could differ materially from those
anticipated in such forward‐looking statements as a result of these
risks and uncertainties. These risks and uncertainties are
described more fully in the section titled “Risk Factors” in
PROCEPT’s filings with the Securities and Exchange Commission (the
“SEC”), including PROCEPT’s quarterly report on Form 10-Q for the
quarter ended September 30, 2021. PROCEPT does not undertake any
obligation to update forward‐looking statements and expressly
disclaims any obligation or undertaking to release publicly any
updates or revisions to any forward‐looking statements contained
herein. These forward-looking statements should not be relied upon
as representing PROCEPT’s views as of any date subsequent to the
date of this press release.
Investor Contact:Gilmartin
GroupMatt Bacso, CFAMatt.bacso@gilmartinir.com
PROCEPT BioRobotics (NASDAQ:PRCT)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
PROCEPT BioRobotics (NASDAQ:PRCT)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024